Trial Profile
Phase 1b Study of Ramucirumab in Combination With Fluoropyrimidines and Platinum-Based Agents in Japanese Patients With Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Capecitabine; Cisplatin; Gimeracil/oteracil/tegafur; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 05 Apr 2017 Results assessing safety, tolerability, pharmacokinetics and efficacy, presented at the 108th Annual Meeting of the American Association for Cancer Research
- 13 Dec 2016 Status changed from active, no longer recruiting to completed.
- 21 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2016.